R heumatoid arthritis (RA) is a systemic inflammatory and autoimmune disease characterized by inflammation in the synovial joints. It typically causes a symmetrical small-joint polyarthropathy that affects the proximal interphalangeal and metacarpophalangeal joints of the hands, wrists and feet (1). The wrist joint is often involved early in the disease course, and is regarded as one of the primary therapeutic targets because appropriate treatment prevents patient disability at work and preserves independent self-care (2). Currently, there is good evidence that early recognition of the disease and intensive treatment using disease-modifying antirheumatic drugs (DMARDs) favours improved outcomes and delays disability in RA patients (3). Nevertheless, when synovial inflammation persists over the follow-up period, joint destruction appears early and leads to rheumatic hand disease, which is characterized by deformity, dysfunction and, frequently, pain (4). Patient responses to DMARDs may be highly variable and it is currently exceedingly difficult to predict which patients will respond to which medication regimen, although current research to identify patient-specific disease signatures via genetic and proteomic approaches is ongoing. Functional and aesthetic compromise, and symptomatic complaints are the most common manifestations of the rheumatoid hand and may affect up to 70% of patients with longstanding disease (5). In such a clinical context, indications for surgery, in order of priority are: impending tendon rupture or severe nerve compression, pain relief, improved function and to correct deformity (5). Although there are clear recommendations from the National Institute for Health and Clinical Excellence (NICE) regarding early surgical referral (6), the systemic, progressive and polyarticular nature of RA elevates the complexity involved in decision-making to higher levels than is found in other areas of hand surgery. The definition of successful surgical intervention according to rheumatologists and hand surgeons varies, and has been a matter of debate for generations of physicians (7-9). Generally, rheumatologists underestimate the benefits of HSPs, while the converse is true for hand surgeons. Moreover, VM Menchaca-Tapia, EM Rodríguez, I Contreras-Yáñez, M Iglesias-Morales, V Pascual-Ramos. Adverse outcomes following hand surgery in patients with rheumatoid arthritis.